• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >T regulatory cells as an immunotherapy for transplantation.
【24h】

T regulatory cells as an immunotherapy for transplantation.

机译：T调节细胞可作为移植的免疫疗法。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Advances in immunosuppressive therapies have made tissue and organ transplantation a common procedure in clinical medicine. However, true donor and recipient tolerance is not regularly achieved and almost all transplant recipients continue to require immunosuppressants throughout life, which is associated with side effects of the drugs. The identification and characterisation of regulatory T cells (Tregs) has recently opened up exciting opportunities for new ways of adoptive immunotherapy in transplantation. CD4+CD25+ Tregs of thymic origin have been shown to be key regulators of unseasoned immune responses in mice and in humans, preventing graft-versus-host disease and organ graft rejection in the transplantation setting. Although these cells can be found in the peripheral blood of healthy individuals, their isolation to a satisfying degree of purity is time-consuming and ineffective. Therefore, a variety of different methods to expand or induce regulatory T cells ex vivo have been advocated. Antigen-specific activation of Tregs is a prerequisite for their optimal function, making the design of new strategies to create and expand antigen-specific Tregs highly desirable. This review will focus on recent advances achieved in the field of transplantation tolerance using naturally occurring Tregs (CD4+CD25+), as well as other Tregs, and will discuss future applications of these cells in immunotherapy.
机译：免疫抑制疗法的进步已使组织和器官移植成为临床医学中的常见程序。但是，不能真正实现真正的供体和受体耐受性，并且几乎所有移植受体在整个生命中仍需要免疫抑制剂，这与药物的副作用有关。调节性T细胞（Tregs）的鉴定和表征最近为在移植中采用过继免疫疗法的新方法开辟了令人兴奋的机会。胸腺来源的CD4 + CD25 + Treg已被证明是小鼠和人类未季节性免疫反应的关键调节因子，可防止移植过程中的移植物抗宿主病和器官移植物排斥。尽管这些细胞可以在健康个体的外周血中找到，但将它们分离到令人满意的纯度是费时且无效的。因此，已经提出了多种不同的体外扩增或诱导调节性T细胞的方法。 Tregs的抗原特异性激活是其最佳功能的先决条件，因此迫切需要设计新策略来创建和扩展抗原特异性Tregs。这篇综述将集中在使用天然存在的Tregs（CD4 + CD25 +）以及其他Tregs在移植耐受领域中取得的最新进展，并将讨论这些细胞在免疫疗法中的未来应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号